These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26443430)

  • 1. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.
    Voog JC; Paulus R; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):212-3. PubMed ID: 26443430
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. Eur Urol 2016;69:58-9: Which patients need treatment intensification?
    Dal Pra A; Spahn M
    Eur Urol; 2016 Apr; 69(4):e74-e75. PubMed ID: 26508311
    [No Abstract]   [Full Text] [Related]  

  • 3. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
    Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
    Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
    Goonewardene SS; Persad R; Young A; Makar A
    Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
    Kirollos MM
    Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
    [No Abstract]   [Full Text] [Related]  

  • 7. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome?
    Chen RC
    Eur Urol; 2016 Feb; 69(2):211-2. PubMed ID: 26395652
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Vincenzo Pagliarulo, Sergio Bracarda, Mario A. Eisenberger, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.
    Cornel EB
    Eur Urol; 2012 Jun; 61(6):e59; author reply e60. PubMed ID: 22386192
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer.
    Kobayashi M; Hatano K; Fukasawa S; Komaru A; Namekawa T; Imagumbai T; Araki H; Hara R; Ichikawa T; Ueda T
    Int J Urol; 2015 May; 22(5):477-82. PubMed ID: 25684541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations.
    Serrano NA; Anscher MS
    Oncology (Williston Park); 2016 Mar; 30(3):229-36. PubMed ID: 26984216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-escalated radiation therapy with and without short-course androgen deprivation for intermediate-risk prostate cancer.
    Schreiber D; Rineer J; Surapaneni A; Navo E; Agarwal M; Nwokedi E; Rotman M; Schwartz D
    Anticancer Res; 2014 Aug; 34(8):4189-93. PubMed ID: 25075045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
    Vis AN; Boevé LMS
    Eur Urol; 2019 May; 75(5):e131-e132. PubMed ID: 30616950
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?
    Zumsteg ZS; Zelefsky MJ
    Lancet Oncol; 2012 Jun; 13(6):e259-69. PubMed ID: 22652234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441.
    Zapatero A; Calvo FA; Gonzalez San-Segundo C; Alvarez A
    Eur Urol; 2022 Dec; 82(6):e177-e178. PubMed ID: 36115773
    [No Abstract]   [Full Text] [Related]  

  • 17. Androgen deprivation therapy and definitive radiotherapy for prostate cancer.
    Mendenhall WM; Henderson RH; Hoppe BS; Nichols RC; Mendenhall NP
    Am J Clin Oncol; 2013 Oct; 36(5):530-4. PubMed ID: 21694574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand?].
    Bellefqih S; Hadadi K; Mezouri I; Maghous A; Marnouche E; Andaloussi K; Elmarjany M; Sifat H; Mansouri H; Benjaafar N
    Cancer Radiother; 2016 Apr; 20(2):141-50. PubMed ID: 26969245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
    Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?
    Boevé LMS; Vis AN
    Eur Urol; 2019 Apr; 75(4):e101-e102. PubMed ID: 30503181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.